Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Semaglutide: Eyesight Loss From Drug Side Effect NAION

February 26, 2025 By Law Offices of Thomas J. Lamb, P.A.

Semaglutide eyesight loss from the drug side effect NAION is being investigated as possible drug injury lawsuits to be filed on behalf of patients against Novo Nordisk, the responsible drug company for Ozempic, Wegovy, and Rybelsus.  The active ingredient for each of those three Novo Nordisk drugs is semaglutide.

There are a couple of recent medical studies about semaglutide being associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) that provide us with more information about this semaglutide eyesight loss drug side effect for Ozempic, Wegovy, and Rybelsus.

The first study was reported in the International Journal of Retina and Vitreous. It found that semaglutide was associated with a higher risk of NAION, having a 2.19 hazard ratio.  The second study, which is in preprint form and not yet published in a peer-reviewed journal (but was posted December 11, 2024, online at medRxiv) “…confirms that use of semaglutide is associated to an increased risk of NAION but also that the excess absolute risk is low.”

People diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) often experience some degree of permanent vision impairment, which can be life-altering.  The Brigham and Women’s Hospital website provides basic medical information about NAION.

Our last article concerning Semaglutide eyesight loss from the drug side effect NAION was “Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect“, posted in December 2024.  An earlier article, “Ozempic Side Effects Include Eye Problems With Possible Vision Loss“, was posted in July 2024.

We are investigating drug injury lawsuits seeking legal compensation for people who have been diagnosed with semaglutide eyesight loss from the drug side effect NAION (non-arteritic anterior ischemic optic neuropathy) while using one of Novo Nordisk’s semaglutide drugs, Ozempic, Wegovy, or Rybelsus.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Ozempic, Rybelsus, Wegovy

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.